Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Cash (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Change in Cash for 8 consecutive years, with -$175.8 million as the latest value for Q1 2026.

  • Quarterly Change in Cash fell 415.73% to -$175.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$4.7 million through Feb 2026, down 117.83% year-over-year, with the annual reading at $137.0 million for FY2025, 147.48% up from the prior year.
  • Change in Cash for Q1 2026 was -$175.8 million at Nurix Therapeutics, down from $168.5 million in the prior quarter.
  • The five-year high for Change in Cash was $168.5 million in Q4 2025, with the low at -$175.8 million in Q1 2026.
  • Average Change in Cash over 5 years is -$507588.2, with a median of -$1.1 million recorded in 2022.
  • The sharpest move saw Change in Cash plummeted 2681.55% in 2023, then skyrocketed 1438.59% in 2025.
  • Over 5 years, Change in Cash stood at $16.9 million in 2022, then decreased by 27.16% to $12.3 million in 2023, then fell by 11.12% to $11.0 million in 2024, then surged by 1438.59% to $168.5 million in 2025, then tumbled by 204.3% to -$175.8 million in 2026.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$175.8 million, $168.5 million, and -$5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.